Polymorphisms in the EGFR pathway as markers for cancer treatment
AssigneeUniversity of Southern California
InventorsHeinz-Josef Lenz, Wu Zhang
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for identifying patients for single agent anti-EGFR therapy. The methods comprise determining the genomic polymorphism present in a predetermined region of a gene of interest and correlating the polymorphism to the predictive response. Patients identified as responsive are then treated with the appropriate therapy.
Claims5
A method for determining whether a human colorectal cancer patient is likely or less likely responsive to a single agent anti-EGFR antibody based therapy selected from Cetuximab or an antibody that binds to the same epitope that Cetuximab binds, comprising screening a suitable cell or tissue sample isolated from said patient for the genetic polymorphism of COX-2 T8473C SNP wherein the presence of the genetic polymorphism of (C/C) for COX-2 T8473C SNP indicates the patient is likely responsive to said single agent anti-EGFR antibody based therapy and wherein the absence of the genetic polymorphism of (C/C) for COX-2 T8473C SNP indicates the patient is less likely responsive to said single agent anti-EGFR antibody based therapy.
Dependencies are inferred from the claim text.